[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100428758":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":60,"collaborators":25,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":25,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":25,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Geisinger Clinic","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"MTA, then Biodentine","EXPERIMENTAL","The participant will receive the standard of care procedure using MTA in on a right primary molar. A left primary molar will then be treated using Biodentine.",[13,14],"Device: Biodentine","Biological: mineral trioxide aggregate (MTA)",{"label":16,"type":10,"description":17,"interventionNames":18},"Biodentine, then MTA","Investigators will prepare and treat a participants right primary molar with Biodentine. The participant will then receive the standard of care procedure using MTA in on a left primary molar.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Biodentine","During a patients procedure, one tooth will receive Biodentine instead of MTA.",[16,9],null,{"type":27,"name":28,"description":28,"armGroupLabels":29,"otherNames":25},"BIOLOGICAL","mineral trioxide aggregate (MTA)",[16,9],[31],{"name":32,"affiliation":5,"role":33},"Gayatri Malik, DMD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","570-271-6355","gmalik1@geisinger.edu",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Samantha R Crissinger","570-271-7499","srcrissinger@geisinger.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Geisinger","RECRUITING","Danville","Pennsylvania","17822","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-76.61273,40.96342,{"lat":56,"lon":55},[59],{"name":32,"role":36,"phone":25,"phoneExt":25,"email":25},{"type":61,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100428758","phase-4-clinical-and-radiographic-success-of-mta-vs-biodentine-100428758",false,"NCT04863222","Clinical and Radiographic Success of MTA vs Biodentine","Clinical and Radiographic Success of Mineral Trioxide Aggregate (MTA) vs Septodont Biodentine in Primary Molars in Pulpotomy and Indirect Pulp Cap Treatments","Inclusion Criteria:\n\n* Male or female patients ages of 2 to ≤12 years.\n* Bilateral symptomatic or asymptomatic vital primary molars with caries approximating or into the pulp.\n* Patient who need a pulpotomy and\u002For indirect pulp cap treatments in two or more quadrants.\n* Parents of patients who can provide consent in English.\n* Patients who need treatment in an operating room setting at Geisinger.\n\nExclusion Criteria:\n\n* Pre-operative radiographic or clinical symptoms associated with irreversible pulpitis or necrotic pulp.\n* Radiographs not displaying furcation region of the tooth.\n* Patients with cardiac conditions who need prophylaxis for infective Endocarditis.\n* Patients with any type of cancer in the past or present.\n* Non-restorable molars.",true,"ALL","2 Years","12 Years",{"count":74,"type":75},646,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.",[81,82],"Indirect Pulp Cap","Pulpotomy","2025-12-22",{"date":85,"type":86},"2025-12-23","ACTUAL",{"date":88,"type":86},"2021-11-12",{"date":90,"type":75},"2026-12-01",{"name":5,"class":6},1]